Evaluation of DeltaMaxx® Microcoil System in Intracranial Aneurysms

July 2, 2014 updated by: Codman & Shurtleff
The primary objective of this registry is to assess the safety and angiographic outcomes of endovascular treatment of intracranial aneurysms using the DeltaMaxx Microcoil System.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Observational

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subjects who have been diagnosed with a ≥ 6 mm intracranial aneurysm.

Description

Inclusion Criteria:

  • Subject age ≥18 and ≤80 with a diagnosis of ruptured or unruptured intracranial aneurysm judged suitable for selective endovascular treatment by coil occlusion during single procedure
  • Investigator intends to use DeltaMaxx Microcoil system during coiling procedure
  • Investigator intends to use only Codman Neuro microcoils during coiling procedure
  • Aneurysm size [largest measurement from the cross sectional images to determine overall aneurysm size, not just the lumen] ≥6 mm
  • If ruptured aneurysm: Hunt and Hess 1, 2, or 3
  • If unruptured aneurysm: Subject grade Modified Rankin Scale 0 - 2
  • The subject or his/her Legally Authorized Representative must voluntarily provide Informed Consent for participation in this study and agree to return for all study visits.

Exclusion Criteria:

  • Prior treatment (surgical or endovascular) of the target aneurysm
  • Subjects with more than one aneurysm (>2 mm) that have been treated with endovascular or clipping techniques in the past 30 days.
  • Subject with social, medical or psychological conditions that interfere with treatment and follow-up evaluation
  • Women who are pregnant or plan to become pregnant during the study
  • Life expectancy less than 12 months.
  • Presence of arteriovenous malformation
  • Fusiform, mycotic, traumatic, or tumoral aneurysms
  • Planned aneurysm treatment by parent vessel occlusion
  • Subject enrolled in any concurrent study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
DeltaMaxx treated Patients
Device: DeltaMaxx Microcoil System

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary Effectiveness Objective - Angiographic Outcomes
Time Frame: 12 Months
The Primary Effectiveness endpoint is the immediate post-procedure and 12-month angiographic occlusion rates assessed by the independent core lab using the modified Raymond-Roy Grading Scale (RRGS) scale
12 Months
Primary Safety Endpoint - Neurological Morbidity and Mortality
Time Frame: 12 months
Neurological Morbidity and Mortality as determined by the NIH Stroke Scale and all-cause mortality, regardless of relationship to the treatment, will be captured over the course of the study
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Packing Density
Time Frame: 24 hours
Packing density as measured by volumetric filling of the aneurysm post-procedure after the coils have been placed as indicated by angiographic films taken at the end of the coiling procedure
24 hours
Recurrence Rate
Time Frame: 12 months
12 months
Re-treatment Rate
Time Frame: 12 months
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Codman & Shurtleff

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Anticipated)

December 1, 2014

Study Registration Dates

First Submitted

September 12, 2013

First Submitted That Met QC Criteria

September 18, 2013

First Posted (Estimate)

September 19, 2013

Study Record Updates

Last Update Posted (Estimate)

July 3, 2014

Last Update Submitted That Met QC Criteria

July 2, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CD-000036-PRO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intracranial Aneurysms

Clinical Trials on DeltaMaxx Microcoil System

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe